Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant-selective degradation by BRAF-targeting PROTACs.

Nature communications - 10 Feb 2021

Alabi Shanique, Jaime-Figueroa Saul, Yao Zhan, Gao Yijun, Hines John, Samarasinghe Kusal T G, Vogt Lea, Rosen Neal, Crews Craig M

Abstract excerpt

Over 300 BRAF missense mutations have been identified in patients, yet currently approved drugs target V600 mutants alone. Moreover, acquired resistance inevitably emerges, primarily due to RAF lesions that prevent inhibition of BRAF V600 with current treatments. Therefore, there is a need for new therapies that target other mechanisms of activated BRAF. In this study, we use the Proteolysis Targeting Chimera...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mice, Nude
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proteolysis

Share to Proto-Oncogene Proteins B-raf

Share to Ubiquitination

Share to Vemurafenib

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33568647
DOI: 10.1038/s41467-021-21159-7
PMCID: PMC7876048

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant-selective degradation by BRAF-targeting PROTACs.PMID 33568647Read ↗

Mutant-selective Degradation by BRAF-targeting PROTACsSemantic proximity Read ↗

Functional characterization of a PROTAC directed against BRAF mutant V600E.Semantic proximity Read ↗

Development of a potent small-molecule degrader against oncogenic BRAFV600E protein that evades paradoxical MAPK activation.Semantic proximity Read ↗

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read ↗

Overcoming the Limits of Inhibition: Mutant-Selective BRAF Degraders.Semantic proximity Read ↗

Overcoming Cancer Drug Resistance Utilizing PROTAC TechnologySemantic proximity Read ↗

Targeting Oncogenic BRAF: Past, Present, and FutureSemantic proximity Read ↗

Progress in RAS-targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras.Semantic proximity Read ↗

Innovative Therapies for Oncogenic KRAS Mutations: Precision Strategies with PROTACs in Cancer Treatment.Semantic proximity Read ↗

Proteolysis targeting chimeras in non-small cell lung cancer.Semantic proximity Read ↗

Targeting the Interplay of Proteins through PROTACs for the Management of Cancer and Associated DisordersSemantic proximity Read ↗

Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020-2023).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.